New nasal vaccine for COVID-19 set to begin clinical trial in the U.S.
A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is poised to enter a phase 1 clinical trial in the U.S. after an investigational new drug ...
EurekAlert!1d
Nasal COVID-19 vaccine based on WashU technology to enter US clinical trials
The adenovirus carries the SARS-CoV-2 protein into the nose ... also a professor of molecular microbiology and of pathology & immunology. Diamond and Curiel’s early studies at WashU Medicine showed ...
Frontiers3d
Synergistic antitumor immune response mediated by paclitaxel-conjugated nanohybrid oncolytic adenovirus with dendritic cell therapy
To address these limitations of DC as immunotherapeutic agent, we have developed a polymeric nanocomplex incorporating (1) oncolytic adenovirus (oAd ... immune response mediated by each treatment, ...
Frontiers27d
Immunogenicity of the recombinant adenovirus fusion-expressing E0-E2 gene of the classical swine fever virus
In addition, human replication-deficient adenovirus type 5 live vector CSF vaccine and chimeric CSFV vaccine can induce complete immune protection. Adenovirus vector vaccines have been the mainstream ...
BMJ14d
Plasma procalcitonin levels in children with adenovirus infection
Correspondence to Varpu Elenius, Department of Paediatrics, Turku University Hospital, Box 52, 20521 Turku, Finland; varpu.elenius{at}utu.fi ...